Meeting
2023 ASCO Breakthrough
Comparisons between HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 ER+ HER2- breast cancer.
Authors
Sung Gwe Ahn
Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
Sung Gwe Ahn , Yoonwon Kook , Soong June Bae , Sae Byul Lee , Joon Jeong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Real-World Evidence/Real-World Data
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 13)
DOI
10.1200/GO.2023.9.Supplement_1.13
Abstract #
13
Poster Bd #
B7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Liquid biopsy identification of ERBB2 amplified and HER2 expressing metastatic breast cancer: Comparison and combination of cell and cell-free platforms.
First Author: Giuseppe Di Caro
Poster
2023 ASCO Annual Meeting
ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis.
First Author: Yueping Liu
Poster
2021 ASCO Annual Meeting
Characterizing demographics, clinical, and genomic characteristics for U.S. patients with HR+, HER2- metastatic breast cancer following progression on a CDK4 and 6 inhibitor.
First Author: Fabrice Andre
Poster
2019 ASCO Annual Meeting
Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data.
First Author: Erika Paige Hamilton